Evidence map›Paper›PMID 26919045›Full record

ArticlePloS one2016

Inflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular Carcinoma.

Te-Sheng Chang, Chi-Long Chen, Yu-Chih Wu, Jun-Jen Liu, Yung Che Kuo, Kam-Fai Lee, Sin-Yi Lin, Sey-En Lin, Shui-Yi Tung, Liang-Mou Kuo and 2 more

Erratum issued Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05293158 (Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma), which is not on this map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05293158 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma

TypeinterventionalSponsorMedical University of GrazRan2024 to 2026Enrolled5ConditionsHepatocellular Carcinoma, HBVArmsHepatect CP 50 I.E./ml infusion solution
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Te-Sheng ChangDepartment of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Chi-Long ChenDepartment of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Yu-Chih WuDepartment of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Jun-Jen LiuSchool of Medical Laboratory Sciences and Biotechnology, Taipei Medical University, Taipei, Taiwan.
Yung Che KuoDepartment of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Kam-Fai LeeDepartment of Pathology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Sin-Yi LinDepartment of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Sey-En LinDepartment of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Shui-Yi TungDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Liang-Mou KuoDepartment of General Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Ying-Huang TsaiDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Yen-Hua HuangDepartment of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Taipei Medical University · TWChiayi Chang Gung Memorial Hospital · TWWan Fang Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression of cancer stemness is believed to reduce the efficacy of current therapies against hepatocellular carcinoma (HCC). Understanding of the stemness-regulating signaling pathways incurred by a specific etiology can facilitate the development of novel targets for individualized therapy against HCC. Niche environments, such as virus-induced inflammation, may play a crucial role. However, the mechanisms linking inflammation and stemness expression in HCC remain unclear. Here we demonstrated the distinct role of inflammatory mediators in expressions of stemness-related properties involving the pluripotent octamer-binding transcription factor 4 (OCT4) in cell migration and drug resistance of hepatitis B virus-related HCC (HBV-HCC). We observed positive immunorecognition for macrophage chemoattractant protein 1 (MCP-1)/CD68 and OCT4/NANOG in HBV-HCC tissues. The inflammation-conditioned medium (inflamed-CM) generated by lipopolysaccharide-stimulated U937 human leukemia cells significantly increased the mRNA and protein levels of OCT4/NANOG preferentially in HBV-active (HBV+HBsAg+) HCC cells. The inflamed-CM also increased the side population (SP) cell percentage, green fluorescent protein (GFP)-positive cell population, and luciferase activity of OCT4 promoter-GFP/luciferase in HBV-active HCC cells. Furthermore, the inflamed-CM upregulated the expressions of insulin-like growth factor-I (IGF-I)/IGF-I receptor (IGF-IR) and activated IGF-IR/Akt signaling in HBV-HCC. The IGF-IR phosphorylation inhibitor picropodophyllin (PPP) suppressed inflamed-CM-induced OCT4 and NANOG levels in HBV+HBsAg+ Hep3B cells. Forced expression of OCT4 significantly increased the secondary sphere formation and cell migration, and reduced susceptibility of HBV-HCC cells to cisplatin, bleomycin, and doxorubicin. Taking together, our results show that niche inflammatory mediators play critical roles in inducing the expression of stemness-related properties involving IGF-IR activation, and the upregulation of OCT4 contributes to cancer migration and drug resistance of HBV-HCC cells. Findings in this paper would provide potential targets for a therapeutic strategy targeting on inflammatory environment for HBV-HCC.

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticCarcinoma, HepatocellularCD68 MoleculeCell MovementCell ProliferationCell SurvivalChemokine CCL2Hepatitis B, ChronicHepatitis B virusHep G2 CellsHomeodomain ProteinsHumansInflammationInsulin-Like Growth Factor ILiver NeoplasmsAntigens, CDAntigens, Differentiation, MyelomonocyticCCL2 protein, humanCD68 antigen, humanCD68 MoleculeChemokine CCL2Homeodomain ProteinsInsulin-Like Growth Factor INanog Homeobox ProteinNANOG protein, humanOctamer Transcription Factor-3picropodophyllinPodophyllotoxinPOU5F1 protein, humanProto-Oncogene Proteins c-aktReceptor, IGF Type 1

Identifiers

PMID26919045
PMCPMC4769282
OpenAlexW2287738221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.